Selling Blue Bottle at a Loss Signals a Real Strategic Shift
Nestle paid roughly $425 million for Blue Bottle Coffee less than a decade ago. The agreed sale price to Centurium Capital, a China-based investment firm, was not disclosed, but BeverageDaily reported it came in below that original acquisition cost. Taking a loss on a named asset is not a routine portfolio decision. It signals that Nestle's leadership concluded the café and CPG model Blue Bottle represents cannot be made to work at the margin levels a company of Nestle's scale requires.
The deal, expected to close in the first half of 2026, covers Blue Bottle's café operations and its consumer packaged goods business. One piece Nestle is keeping: the rights to sell Nespresso-compatible pods under the Blue Bottle brand. That carve-out is telling. The pods can be sold through grocery and Nespresso's direct channel, fit the same supply chain as the rest of the coffee business, and carry higher margins than running cafés. Nestle's stated priority is what its leadership describes as "scalable, high-margin coffee formats: pods, instant, and ready-to-drink," per BeverageDaily.
If you are tracking competitive dynamics in the French coffee market, this move matters. France is historically Nespresso's largest single market, and Nestle's decision to sharpen its focus on pods rather than service-led formats reinforces the competitive pressure on Keurig Dr Pepper's newly formed Global Coffee Co. and on Lavazza's French push.
The Alt-Cocoa Position Is Quiet but Structural
Separate from the coffee story, Nestle has been building a position in cocoa alternatives. The company is working with ChoViva, a sunflower-based cocoa ingredient made by Planet A Foods, alongside Barry Callebaut, per ConfectioneryNews coverage of the alt-chocolate space. ChoViva is designed to replicate cocoa's functional and flavour properties using sunflower seeds, which are grown in a far more stable commodity market than cocoa.
The broader field now includes cell-cultivated cocoa butter from Celleste Bio, partnered with Mondelez, and fermented carob reworked for flavour depth. Lindt, Cargill, and Barry Callebaut are all spending in this space. That is not a pilot cluster. When five or more major players in a category are backing competing technologies simultaneously, the capital allocation has crossed from experimentation into structural hedging.
Cocoa price volatility is the obvious driver. For Nestle, which sells chocolate confectionery globally, an input that swings hard in price is a real commercial risk. Locking in alternative formulation routes, even if consumer adoption is still unproven, gives the procurement and product teams optionality if cocoa costs spike again or if sustainability pressure on cocoa sourcing intensifies.
Consumer acceptance of alt-cocoa at scale has not been demonstrated. That is the honest caveat. Taste parity with real chocolate is a high bar, and shoppers in premium segments, particularly in Germany where Lindt, Ritter Sport, and private label premium compete on quality cues, will not trade down on flavour.
What to Watch
Two things are worth tracking closely over the next 12 to 18 months.
First, whether Nestle accelerates further divestiture of non-core or underperforming brands. The Blue Bottle exit fits a pattern of big food companies shedding service-adjacent or lifestyle assets that looked attractive in a lower interest rate environment but have not delivered. If you are a category manager or commercial director working with Nestle in any market, portfolio stability in adjacent categories is worth reassessing.
Second, whether any of the alt-cocoa investments move from ingredient trials into named product launches. ChoViva appearing on a Nestle product label in a major European grocery market would be a signal that the technology has cleared Nestle's internal quality and consumer acceptance bar. That would shift the conversation from "investment in alternatives" to "reformulation at scale," with real implications for the competitive set in chocolate confectionery.
For now, Nestle's M&A posture in 2026 is consolidation and focus: fewer formats, higher margins, and structural hedges on the input side. That is a coherent commercial strategy, even if some of the individual bets are still early.